GW Pharmaceuticals (Nasdaq: GWPH) tremendous 700% one year run is showing no signs of slowing down. The drug developer, often lumped in with marijuana stocks due to its focus on the cannabinoid system, received an FDA fast track designation for its orphan drug Epidiolex. This drug is hoping to treat Dravet and Lennox- Gastaut syndromes, both are rare forms of pediatric epilepsy and have a significant unmet need for treatments.
Epidiolex as a wholly owned drug has significant potential for GW and could cross $500 million in global peak sales, easily supplanting its current approved drug Sativex as the company's flagship product.
In this episode of Market Checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss the recent regulatory good news, the market potential for Epidiolex and why Fools should be watching this stock closely.